Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 7th Preview)
-
Vertex expands endocrinology footprint with Crinetics buyout
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion, its largest-ever deal, to deepen a commercial endocrinology portfolio. Vertex will pick up Crinetics’ launched acromegaly therapy Palsonify (paltusotine) and a late-stage congenital adrenal hyperplasia program, with the transaction expected to close in the third quarter of 2026 after board approval. Vertex plans to fund the purchase with cash and $4.5 billion of bridge financing committed by Bank of America and Morgan Stanley. The company said the combined assets could generate peak sales of more than $5 billion, positioning them as margin-accretive for Vertex’s specialty endocrinology focus. Analysts said the price underscores strategic urgency in rare endocrine disease commercialization. The Crinetics deal also lands as Vertex continues to scale a pipeline built around oral and receptor-targeted biology. Vertex estimates that Palsonify and atumelnant together carry a substantial revenue upside if late-stage development executes and payers support uptake in rare disease settings. For Crinetics, the acquisition provides an accelerated path from commercial execution to broader scale through Vertex’s infrastructure, while investors focus on integration timing and the trajectory of the CAH program into confirmatory and regulatory steps.
-
Bristol Myers confronts Krazati confirmatory setback in colorectal cancer
Bristol Myers Squibb disclosed that the confirmatory phase 3 Krystal-10 trial of Krazati (adagrasib) plus Eli Lilly’s Erbitux (cetuximab) failed to hit statistical significance in KRAS G12C-mutated metastatic colorectal cancer. The study enrolled 461 previously treated patients and missed dual primary endpoints of progression-free survival and overall survival. Krazati’s initial U.S. accelerated approval in CRC came in combination with Erbitux in June 2024, requiring confirmatory trials to secure full approval. BMS said the phase 3 results presented at the ESMO Gastrointestinal Cancers Congress 2026 in Munich supported the clinical activity of the combination, but the company is now discussing “next steps” with regulators. BMS emphasized that lung cancer remains the larger potential market for Krazati, pointing to two first-line NSCLC pivotal trials still underway. The company’s next regulatory moves for colorectal cancer will depend on how regulators interpret the confirmatory evidence versus the accelerated approval framework. The setback raises pressure on how quickly BMS can transition accelerated oncology assets into durable, registrable benefit profiles across indications where patient populations are smaller and endpoints are harder to mature.
-
Novartis scales differentiated ADC payload platform with Myricx deal
Novartis agreed to pay $1.1 billion upfront to acquire Myricx Bio, adding a preclinical antibody-drug conjugate payload platform built on N-myristoyltransferase (NMT) inhibitors. The Swiss pharma said the deal could include up to $400 million in additional milestones, with closing expected in the second half of 2026. Myricx’s payload approach is positioned as an orthogonal alternative to conventional chemotherapy warheads used in many ADCs, with lead candidates designed for HER2- and B7-H3-positive solid tumors. Novartis said two programs are slated to enter clinical development before the end of the year, reflecting a rapid intent to move beyond platform validation into human data. The acquisition aligns with Novartis’ broader oncology strategy to expand precision modalities and address resistance and toxicity limitations in today’s ADC market. The company said Myricx’s technology could broaden ADC use across multiple tumor settings if the payload delivers differentiated efficacy and tolerability. Investors also noted the deal’s timing as the ADC space continues to consolidate, with Big Pharma seeking differentiated mechanisms to compete against established leaders and pipeline incumbents.
-
Kailera/Hengrui deliver Phase 3 toplines for oral GLP-1 in China
Kailera Therapeutics said its oral GLP-1 asset achieved primary endpoints in two Phase 3 obesity and diabetes trials in China, supporting Hengrui Pharma’s path to regulatory submissions. The trials read out 11% weight loss and met key efficacy goals in the obesity study, while the diabetes program posted encouraging efficacy results. Separate reports on the late-stage programs highlighted gastrointestinal side effects as a key safety concern for the daily oral therapy, with analysts pointing to tolerability as the major differentiator to watch against injectable GLP-1s. The topline results strengthen the competitive outlook for oral incretin approaches in China, where oral formulations may benefit adherence and broaden eligibility. The next milestone will be whether the safety profile sustains through registrational datasets. For Hengrui, the clinical readouts add momentum to its specialization in metabolic disease drug development and increase pressure on competitors to show oral-efficacy and tolerability advantages.
-
Whitehawk expands ADC pipeline through Biocytogen bispecific licensing
Whitehawk Therapeutics entered a development deal with China-headquartered Biocytogen to build bispecific antibody-drug conjugates. The collaboration grants Whitehawk access to five Biocytogen-supplied bispecific antibodies, with Whitehawk evaluating candidates and retaining options to advance ADC programs into its pipeline. Biocytogen’s RenLite platform is designed to discover and optimize fully human bispecific antibodies for diverse target pairings, intended to support differentiated ADC targeting profiles. The deal includes upfront and milestone payments, though July 7 details were not disclosed. The companies positioned the agreement as an expansion of Biocytogen’s use of its bispecific portfolio in ADC development, building on prior Biocytogen partnerships that have included earlier deal activity in 2024. Whitehawk said it expects new ADC INDs within 12–24 months, suggesting fast-track preclinical generation. For the ADC supply chain, the transaction underscores continued outsourcing of antibody discovery and optimization capabilities to strengthen platform differentiation and accelerate IND-enabling work.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.